An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)
| Excerpt | Reference |
|---|
| "Open-angle glaucoma is frequently observed in patients with acromegaly suggesting that the somatotropic hormone might facilitate a condition of glaucoma." | ( Altomonte, L; Ghirlanda, G; Greco, AV; Manna, R; Rebuzzi, AG; Ricci, B, 1979) |
| "Malignant glaucoma is a serious complication of surgery for angle-closure glaucoma." | ( Mills, DW; Willis, NR, 1978) |
| "Mixed glaucoma is a rare, fortuitous combination of open-angle and angle-closure glaucoma rather than a distinct entity, and it might be advisable to avoid the term, which tends to be used for primary glaucomas of uncertain classification." | ( Hyams, SW; Keroub, C; Pokotilo, E, 1977) |
| "Pupillary-block glaucoma is the first postoperative complication seen following the implantation of an intraocular lens, and in our series occurred at an incidence of 3-8%." | ( Kaback, M; Werner, D, 1977) |
| "Closed-angle glaucoma is the result of two mechanisms acting either separately or in combination: 1." | ( Mapstone, R, 1976) |
| "Acute angle-closure glaucoma is best treated by iridectomy." | ( Grehn, F, 1990) |
| "Although phacolytic glaucoma is well known and the clinical picture is well recognized, the nature of the polychromatic hyperrefringent granules is less well understood." | ( Brooks, AM; Gillies, WE; Grant, G, 1990) |
| "Glaucoma is the most serious long-term complication of the surgical method and occurs most frequently in aphakic eyes." | ( Billington, BM; Leaver, PK, 1989) |
| "Glaucoma is described, and the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of betaxolol and levobunolol in comparison with timolol are reviewed." | ( Lesar, TS, 1987) |
| "Glaucoma is a potentially blinding ocular disease that commonly affects elderly persons." | ( Brubaker, RF; Johnson, DH, 1986) |
| "Cataract and glaucoma are the most important complications." | ( O'Connor, GR, 1985) |
| "Secondary vascular glaucoma is increased intraocular pressure due to venous obstruction in or outside the eye." | ( de Keizer, RJ, 1983) |
| "Pupillary block glaucoma is a potential complication of implantation." | ( Baras, I; Barasch, KR; Galin, MA; Obstbaum, SA, 1981) |
| "This glaucoma is usually resistant to medical therapy and can lead to blindness." | ( Alward, WL; Héon, E; Kalenak, JW; Sheffield, VC; Sheth, BP; Stone, EM; Streb, LM; Sunden, SL; Taylor, CM, 1995) |
| "Glaucoma is a potentially blinding disease." | ( Serle, JB, 1994) |
| "A history of glaucoma is still taught to be the prime contraindication to its use, although the only individuals at risk are those with undiagnosed and therefore untreated angle closure glaucoma (ACG), who will not give a positive history." | ( Aylward, GW; Fink, AM, 1995) |
| "Glaucoma is a major cause of blindness in developing nations." | ( Krishnadas, R; Michon, J; Ramakrishnan, R; Robin, AL, 1993) |
| "Our chronic glaucomas are frequent in male with an average of age of 60,5 years." | ( Auzemery, A; Bernardin, P; Rabenantoandro, C, 1994) |
| "Glaucoma is a serious disease that may cause a decrease in peripheral vision as well as blindness." | ( Aguinaga Ontoso, E; Aguinaga Ontoso, I; Fernandez Fernandez, LR; Guillen Grima, F, 1997) |
| "Primary juvenile glaucoma is a rare form of glaucoma that typically affects individuals between 3 and 20 years of ages and is inherited as an autosomal dominant trait." | ( Del Bono, EA; Hutchinson, BT; Schuman, JS; Walton, DS; Wiggs, JL, 1995) |
| "Glaucoma is a group of ocular disorders leading to reduced visual capabilities and sometimes blindness." | ( Graff, C; Jerndal, T; Wadelius, C, 1997) |
| "Glaucoma is a significant complication after stage 3 macular hole surgery even without adjunctive therapy." | ( Chen, CJ, 1998) |
| "Glaucoma is characterized by raised intraocular pressure and is responsible for retinal ganglion cell and, possibly, photoreceptor degeneration." | ( Janssen, P; Moore, S; Naskar, R; Thanos, S; Thiel, HJ, 1996) |
| "Glaucoma is in most of cases initially treated with drugs, viz." | ( Hoyng, PF; Rasker, MT, 1998) |
| "Glaucoma is a frequent and often a refractory complication of PPV with SOI and has a multifactorial etiology." | ( Dandona, L; Goyal, M; Honavar, SG; Majji, AB; Naduvilath, T; Sen, PK, 1999) |
| "Cataract and glaucoma are two very common conditions that frequently are coincident within the same patient." | ( Samuelson, TW, 1996) |
| "Glaucomas are a major cause of blindness." | ( Anderson, MG; Chang, B; Davisson, MT; Hawes, NL; Heckenlively, JR; John, SW; Roderick, TH; Savinova, O; Smith, RS; Zabaleta, A, 1999) |
| "Most therapy for glaucoma is directed at the management of the intraocular pressure (IOP)." | ( Dreyer, EB; Gorla, MS; Vorwerk, CK, 1999) |
| "Glaucoma is an optic neuropathy with cupping of the optic disk, degeneration of retinal ganglion cells, and characteristic visual field loss." | ( Becker, B; Neufeld, AH; Sawada, A, 1999) |
| "Glaucoma is among the most serious complications of familial amyloid polyneuropathy." | ( Adams, D; Bousquet, A; Frau, E; Labétoulle, M; Lautier-Frau, M; Offret, H; Saindelle-Ribeaudeau, F, 2000) |
| "Glaucoma is a leading cause of irreversible blindness in Canada." | ( Héon, E; Klose, R; Levin, AV; Martin, SN; Priston, M; Sutherland, J, 2000) |
| "Glaucoma is caused by a sustained elevation of intraocular pressure due to the decreased drainage of aqueous humor from the anterior chamber of the eye." | ( Ho-Shing, D, 2000) |
| "Glaucoma is a common disease but its molecular etiology is poorly understood." | ( Anderson, MG; Chang, B; Davisson, M; Hawes, NL; Heckenlively, JR; John, SW; Savinova, OV; Smith, RS; Wilpan, R; Zabaleta, A, 2001) |
| "The glaucomas are a group of optic neuropathies comprising the leading cause of irreversible blindness worldwide." | ( Chintala, SK; Fini, ME; Schuman, JS; Wang, N, 2001) |
| "Glaucoma is a complex disease with a number of risk factors and mechanisms leading to ganglion cell death." | ( Hartwick, AT, 2001) |
| "Glaucoma is characterized by increased intraocular pressure (IOP) in some but not all cases." | ( Head, KA, 2001) |
| "Currently glaucoma is considered a neurodegenerative disease in which retinal ganglion cells (RGC) slowly die, likely in the apoptotic mechanism." | ( Grieb, P; Rejdak, R, 2002) |
| "Cataract and glaucoma are both common conditions and are often present in the same patient." | ( Bass, EB; Congdon, N; Friedman, DS; Jampel, HD; Kempen, JH; Levkovitch-Verbin, H; Lubomski, LH; Quigley, H; Robinson, KA, 2002) |
| "Glaucoma is the major cause of irreversible blindness throughout the world." | ( Cordeiro, MF, 2003) |
| "Glaucoma is not a rare condition in patients with FAP, especially because liver transplantation now enables patients with FAP to live longer." | ( Ando, E; Ando, Y; Arimura, K; Fukushima, M; Hirata, A; Kimura, A; Koga, T; Negi, A; Tanihara, H, 2003) |
| "Glaucoma is a term encompassing a variety of diseases that end in the death of retinal ganglion cells (RGC)." | ( Barzilai, A; Harness, E; Holdengreber, V; Kimron, M; Nizan, A; Shirvan, A; Smorodinsky, NI; Solomon, AS; Yaakobowicz, M, 2003) |
| "Glaucoma is an optic neuropathy that is associated with elevated intraocular pressure in most patients." | ( Liu, B; Neufeld, AH, 2003) |
| "Glaucoma is a neurodegenerative disease typified by progressive loss of retinal ganglion cells (RGCs)." | ( Lipton, SA, 2003) |
| "Normal tension glaucoma is a clinical condition in which the optic nerve is pathologically excavated and the visual field is disturbed." | ( Bauer, P; Eichler, H; Findl, O; Groke, I; Schmetterer, L; Sycha, T; Vass, C, 2003) |
| "Glaucoma is a common eye disease associated with elevated intraocular pressure (IOP)." | ( Dawson, DG; Faha, B; Gleiser, J; Heatley, G; Kaufman, PL; Kiland, J; Maneval, D; Nickells, RW; Schlamp, CL; Seeman, J, 2004) |
| "Glaucoma is a chronic optic neuropathy in which retinal ganglion cells die over a number of years." | ( Casson, R; Chidlow, G; DeSantis, L; Osborne, NN; Schmidt, KG; Wood, JP, 2004) |
| "Glaucoma is a progressive optic neuropathy with characteristic optic disc changes, retinal ganglion cell loss and progressive visual field defects." | ( Naskar, R; Thanos, S, 2004) |
| "Glaucoma is the main cause of blindness in the developed countries." | ( Merwid-Lad, A; Misiuk-Hojło, M; Pieśniewska, M; Szaliński, M; Trocha, M, 2004) |
| "Medication of glaucoma is only initially effective." | ( Goś, R; Jurowski, P; Kapica, A; Zdzieszyńska, M, 2004) |
| "Glaucoma is an optic neuropathy in which retinal ganglion cells die probably through an apoptotic process." | ( Campanelli, J; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, P; Sánez, DA, 2004) |
| "Glaucoma is defined as an optic neuropathy with characteristic changes in the optic nerve head and ultimate loss of visual field." | ( Hara, H; Shimazawa, M; Toriu, N, 2004) |
| "Glaucoma is one of the most common causes of visual loss despite successful congenital cataract surgery." | ( Mandal, AK; Netland, PA, 2004) |
| "Congenital glaucoma is a well-recognized entity that can occur in the presence of anterior segment dysgenesis." | ( Al-Khaier, A; Dansingani, KK; Nischal, KK; Russell-Eggitt, IM, 2005) |
| "Glaucoma is an important cause of ocular morbidity among aphakes and pseudophakes in this rural population of south India." | ( Arvind, H; Baskaran, M; George, R; McCarty, C; Paul, PG; Raju, P; Ramesh, SV; Vijaya, L, 2005) |
| "Glaucoma is a condition affecting one or both eyes with raised intraocular pressure (IOP)." | ( Buchholz, P; Christensen, TL; Holmstrom, S; Hommer, AB; Poulsen, PB; Tuil, E; Walt, J, 2005) |
| "Awareness of glaucoma is very poor in the rural areas of southern India." | ( Kovai, V; Krishnaiah, S; Rao, GN; Shamanna, BR; Srinivas, M; Thomas, R, 2005) |
| "Glaucoma is generally managed by decreasing the intraocular pressure (IOP) to a level believed to prevent further damage to the optic disc and loss of visual field." | ( Christensen, TL; Holmstrom, S; Poulsen, PB; Vetrugno, M; Walt, JG, 2005) |
| "Congenital glaucoma is generally related to an iridocorneal angle malformation, with an obstacle to aqueous humor outflow." | ( Dureau, P, 2006) |
| "Glaucoma is a common blinding disease worldwide." | ( Attarzadeh, A; Hosseini, H; Nowroozizadeh, S, 2006) |
| "Glaucoma is medical and social problem in many countries." | ( Golovacheva, MO, 2006) |
| "Glaucoma is a chronic and progressive optic nerve neuropathy involving the death of retinal ganglion cells (RGCs)." | ( Hernández, M; Urcola, JH; Vecino, E, 2006) |
| "Glaucoma is one of the most common causes of irreversible blindness worldwide." | ( Farvardin, M; Hosseini, H; Mehryar, M, 2007) |
| "Glaucoma is a common disease of the eye, a key characteristic consequence of which is the death of retinal ganglion cells." | ( Macnab, L; Pow, DV; Ruiz, G; Sullivan, RK; Woldemussie, E, 2006) |
| "Glaucoma is a chronic neurodegenerative disease of the retina, characterized by the degeneration of axons in the optic nerve and retinal ganglion cell apoptosis." | ( Dietz, JA; Janssen, KT; Li, Y; Nickells, RW; Schlamp, CL, 2006) |
| "The risk of glaucoma is significant, and additional study is required to further characterize this and other risks." | ( Ai, E; Fu, AD; Goff, MJ; Johnson, RN; Jumper, JM; McDonald, HR; Yang, SS, 2006) |
| "ARM-associated glaucoma is a bilateral anterior segment dysgenesis disease that affects males and females equally." | ( Dinu, I; Strungaru, MH; Walter, MA, 2007) |
| "Glaucoma is the second leading cause of blindness in the world." | ( Cao, W; Chodosh, J; Ge, J; Li, F; Sarkisian, SR; Tomita, H; Zaharia, A; Zhou, X, 2007) |
| "Glaucoma is a major cause of vision impairment, which arises from the sustained and progressive apoptosis of retinal ganglion cells (RGC), with ocular hypertension being a major risk or co-morbidity factor." | ( Birman, E; Saragovi, HU; Shi, Z, 2007) |
| "Although glaucoma is often associated with elevated intraocular pressure (IOP), IOP elevation is not detected in a significant subset of glaucomas, such as normal tension glaucoma (NTG)." | ( Aihara, M; Harada, C; Harada, T; Mitani, A; Nakamura, K; Namekata, K; Okumura, A; Quah, HM; Saeki, T; Tanaka, K; Yoshida, H, 2007) |
| "Glaucoma is a progressive optic neuropathy that is the leading cause of irreversible blindness in the world." | ( Forbes, M; Song, BJ; Tsai, JC; Wu, L, 2007) |
| "Glaucoma is a leading cause of irreversible visual loss." | ( Fechtner, RD; Khouri, AS; Realini, T, 2007) |
| "Glaucoma is a kind of optic neuropathy where selective retinal ganglion cell loss is the major hallmark." | ( Dorecka, M; Rokicki, W; Romaniuk, W, 2007) |
| "Glaucoma is a neurodegenerative disease of the visual system." | ( Chan, KC; Fu, QL; Hui, ES; So, KF; Wu, EX, 2008) |
| "Glaucoma is a neurodegenerative disease for which the neuropathic pathology has been studied since 1972." | ( Levin, LA; Peeples, P, 2008) |
| "Glaucoma is the main complication and occurred immediately after surgery, suggesting a possible direct mechanical effect of the large BDI lens." | ( Aslam, SA; Ficker, LA; MacLaren, RE; Wong, SC, 2008) |
| "Glaucoma is a progressive optic neuropathy and is the leading cause of blindness in the United States and other industrialized countries." | ( Aslan, M; Cort, A; Yucel, I, 2008) |
| "Glaucoma is a neurodegenerative disease of the visual system characterized by the elevation of intraocular pressure." | ( Chan, KC; Fu, QL; Guo, H; So, KF; Wu, EX, 2008) |
| "Glaucoma is a group of irreversible blinding eye diseases affecting over 70 million people worldwide." | ( Bhattacharya, SK; Govindarajan, B; Laird, J; Salomon, RG; Sherman, R, 2008) |
| "Glaucoma is a long-term ocular neuropathy defined by optic disc or retinal nerve fiber structural abnormalities and visual-field defects." | ( Pasquale, N; Scuderi, GL, 2008) |
| "Glaucoma is a visual disorder characterized by progressive loss of retinal ganglion cells (RGCs), which is often associated with high intraocular pressure." | ( Lipton, SA; Seki, M, 2008) |
| "Glaucoma is a worldwide leading cause of irreversible vision loss characterized by progressive death of retinal ganglion cells (RGCs)." | ( Bagetta, G; Cavaliere, F; Cerulli, A; Corasaniti, MT; Fazzi, E; Gliozzi, M; Morrone, LA; Nucci, C; Rombolà, L; Russo, R, 2008) |
| "Glaucoma, is a progressive optic neuropathy often associated with increased intraocular pressure (IOP) and characterized by progressive death of retinal ganglion cells (RGCs)." | ( Bagetta, G; Cavaliere, F; Corasaniti, MT; Morrone, LA; Nucci, C; Russo, R; Sakurada, S; Watanabe, C, 2008) |
| "Glaucoma is a leading cause of worldwide blindness." | ( Hendrick, AM; Kahook, MY, 2008) |
| "Glaucoma is the world's second leading cause of bilateral blindness with progressive loss of vision due to retinal ganglion cell death." | ( Anholt, RR; Ayroles, JF; Carbone, MA; Mackay, TF; Magwire, MM; Morozova, TV; West, SA; Yamamoto, A, 2009) |
| "Glaucoma is a neurodegenerative pathology that affects the optic nerve producing blindness." | ( Alarma-Estrany, P; Mediero, A; Pintor, J, 2009) |
| "Glaucoma is one of the most frequent causes of blindness in the world." | ( Funk, J, 2009) |
| "Glaucoma is a leading cause of visual impairment and blindness worldwide." | ( Liu, JH; Sit, AJ, 2009) |
| "Glaucoma is a group of genetically heterogeneous neurodegenerative disorders causing the degeneration of the ganglion neurons of the retina." | ( Cho, KI; Ferreira, PA; Friedman, J; McKinnon, S; Searle, K; Tserentsoodol, N; Walsh, MM; Yeh, A; Yi, H, 2009) |
| "Glaucoma is a heterogeneous group of optic neuropathies that manifests by optic nerve head cupping or degeneration of the optic nerve, resulting in a specific pattern of visual field loss." | ( Babrzadeh, F; Elahi, E; Fazlali, Z; Narooie-Nejad, M; Nilforushan, N; Paisán-Ruiz, C; Paylakhi, SH; Rezaei Kanavi, M; Ronaghi, M; Shojaee, S; Suri, F; Yazdani, S, 2009) |
| "Glaucoma is a disease characterized by progressive optic neuropathy resulting in retinal ganglion cell death, which affects approximately 68 million people worldwide." | ( Ehrlich, R; Harris, A; Kheradiya, NS; McCranor, L; Risner, D; Siesky, B, 2009) |
| "Although glaucoma is often associated with elevated intraocular pressure, recent studies have shown a relatively high prevalence of normal tension glaucoma (NTG) in glaucoma patient populations." | ( Fuse, N; Guo, X; Harada, C; Harada, T; Kikushima, K; Kimura, A; Kohyama, K; Matsumoto, Y; Mitamura, Y; Namekata, K; Tanaka, K, 2009) |
| "Drug therapy for glaucoma is based on lowering of intraocular pressure regardless of the pressure level, at which the disease has been diagnosed." | ( Määttä, M; Puska, P, 2009) |
| "Glaucoma is a disease of the optic nerve caused by the increase in the intraocular pressure of the eye." | ( Acharya U, R; Bhat, PS; Lim, TC; Nayak, J; Shetty, N, 2009) |
| "Glaucoma is the second leading cause of blindness in the world, after cataracts, and the leading cause of irreversible blindness, but many aspects of its pathogenesis remain unknown." | ( Bagnis, A; Izzotti, A; Recupero, SM; Saccà, SC, 2009) |
| "Glaucoma is a neurodegenerative disease in which elevated intraocular pressure (IOP) leads to progressive loss of retinal ganglion cells (RGCs) and blindness." | ( Fileta, J; Grosskreutz, CL; Huang, W; Qu, J; Rawe, I, 2010) |
| "Glaucoma is a leading cause of blindness worldwide." | ( Akahori, M; Barnett, EM; Chang, Q; Fujikawa, K; Fukaya, M; Inoue, K; Iwata, T; Kadotani, H; Swat, W; Watanabe, M, 2010) |
| "Normal tension glaucoma is a clinical condition in which the optic nerve is pathologically excavated and the visual field is disturbed." | ( Bauer, P; Eichler, HG; Findl, O; Groke, I; Schmetterer, L; Sycha, T; Vass, C, 2010) |
| "Glaucoma is a leading cause of blindness." | ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010) |
| "Glaucoma is a disease in which retinal ganglion cells (RGCs) die leading ultimately to blindness." | ( Grosskreutz, CL; Qu, J; Wang, D, 2010) |
| "Glaucoma is the second leading cause of blindness worldwide." | ( Good, TJ; Kahook, MY, 2010) |
| "Glaucoma is an optic neuropathy of unknown origin." | ( Garhofer, G; Schmetterer, L; Schmidl, D, 2011) |
| "Glaucoma is characterized by loss of retinal nerve fibers, structural changes to the optic nerve, and an associated change in visual function." | ( Flanagan, JG; Hudson, C; Venkataraman, ST, 2010) |
| "Open-angle glaucoma is the most common optic nerve head neuropathy and is associated with a loss of retinal ganglion cells and visual field damage." | ( Fromm, M; Rosenthal, R, 2011) |
| "Glaucoma is a frequent ophthalmologic condition leading to chronic progressive optic neuropathy, which can result in visual impairment and blindness." | ( Agorastos, A; Huber, CG, 2011) |
| "Glaucoma is a leading cause of blindness." | ( Bui, BV; Vingrys, AJ; Wong, VH, 2011) |
| "Glaucoma is a serious sight-threatening disorder aptly named the Silent thief of sight." | ( Khurana, M; Ramakrishnan, R, 2011) |
| "Congenital glaucoma is a global problem and poses a diagnostic and therapeutic challenge to the ophthalmologist." | ( Chakrabarti, D; Mandal, AK, 2011) |
| "Glaucoma is one of the leading causes of blindness worldwide." | ( Parikh, RS; Parikh, SR, 2011) |
| "Glaucoma is an age-related optic neuropathy involving sensitivity to ocular pressure." | ( Calkins, DJ; Crish, SD, 2011) |
| "Glaucoma is a devastating neurodegenerative disease, which can lead to vision loss and is associated with irreversible damage to retinal ganglion cells." | ( Fischer, ME; McKee, CT; Murphy, CJ; Reilly, CM; Russell, P; Shah, NM; Wood, JA, 2011) |
| "Glaucoma is the leading cause of irreversible blindness worldwide." | ( Almasieh, M; Casanova, C; Di Polo, A; Kelly, ME; Zhou, Y, 2010) |
| "Glaucoma is one of the most common neurodegenerative diseases." | ( Barbay, JM; Barres, BA; Clark, AF; Hibbs, M; Howell, GR; John, SW; King, BL; Kneeland, SC; Libby, RT; Macalinao, DG; Marchant, JK; Soto, I; Sousa, GL; Stevens, B; Walden, M, 2011) |
| "Glaucoma is a common eye disease that can cause irreversible blindness if not diagnosed and treated in the early stages of progression." | ( Hakkola, J; Mäenpää, J; Pelkonen, O; Vapaatalo, H; Volotinen, M, 2011) |
| "Glaucoma is a slowly progressive optic neuropathy that is one of the leading causes of legal blindness throughout the world." | ( Pinar-Sueiro, S; Rodríguez-Puertas, R; Vecino, E, 2011) |
| "Glaucoma is a leading cause of blindness worldwide, characterized by retinal ganglion cell degeneration and damage to the optic nerve." | ( Belforte, N; de Zavalía, N; Fernandez, DC; Golombek, DA; Lanzani, MF; Plano, SA; Rosenstein, RE; Salido, E; Sarmiento, MI, 2011) |
| "However, glaucoma is the most common ocular complication of SWS." | ( Basler, L; Sowka, J, 2011) |
| "Glaucoma is the second leading cause of blindness worldwide, affecting more than 60 million people." | ( Acar, N; Bretillon, L; Bron, A; Creuzot-Garcher, C; Fourgeux, C, 2011) |
| "Glaucoma is one of the leading causes of blindness and visual disability." | ( Covert, DW; Iskedjian, M; Walker, JH, 2011) |
| "Glaucoma is the second leading cause of blindness." | ( Dyda, W; Fiedorowicz, M; Grieb, P; Rejdak, R, 2011) |
| "Glaucoma is a leading cause of blindness affecting as many as 2." | ( Buck, J; Hess, K; Lee, YS; Levin, LR; Marmorstein, AD; Marmorstein, LY; Tresguerres, M, 2011) |
| "Glaucoma is an optic nerve disease resulting in loss of vision." | ( Aung, T; Baskaran, M; Cheng, J; Lee, BH; Liu, J; Tao, D; Wong, DW; Wong, TY, 2011) |
| "The risk to develop glaucoma is enhanced by increases in IOP, which result from deranged flow of aqueous humor." | ( Ellis, DZ, 2011) |
| "Glaucoma is the second leading cause of blindness globally, representing a significant public health concern." | ( Konstas, AG; Quaranta, L; Realini, T, 2012) |
| "Glaucoma is a chronic progressive optic neuropathy, which can result in visual impairment and blindness." | ( Colligris, B; Crooke, A; Pintor, J, 2012) |
| "Glaucoma is an eye condition mainly developed from an excessive intraocular pressure." | ( Benitez-del-Castillo, JM; Colligris, B; Crooke, A; Escribano, J; García-Feijoo, J; Gasull, X; Herrero-Vanrell, R; Pintor, J, 2012) |
| "Glaucoma is a progressive optic neuropathy of unknown origin." | ( Cherecheanu, AP; Garhofer, G; Schmetterer, L; Schmidl, D; Werkmeister, R, 2013) |
| "Glaucoma is the second major cause of blindness in the world after cataract." | ( Abou-Jaoude, M; Carbia, BE; Chauhan, A; Jung, HJ; Plummer, C, 2013) |
| "Glaucoma is a progressive optic neuropathy frequently associated with elevated intraocular pressure, ocular vascular changes and extracellular matrix remodelling at the optic nerve head and in the trabecular meshwork." | ( Gerber, AL; Harris, A; Prendes, MA; Siesky, B; Wirostko, BM, 2013) |
| "Glaucoma is the leading cause of irreversible blindness in industrialized countries and comprises a group of diseases characterized by progressive optic nerve degeneration." | ( Aslan, M; Dogan, S; Kucuksayan, E, 2013) |
| "Glaucoma is a worldwide disease and the second leading cause of blindness." | ( Bar-Yehuda, S; Cohen, S; Fishman, P, 2013) |
| "Glaucoma is one of the major causes of blindness, affecting together with age-related macular degeneration > 70 million people worldwide." | ( Carta, F; Masini, E; Scozzafava, A; Supuran, CT, 2013) |
| "Glaucoma is an eye disease that can lead to irreversible visual impairment." | ( Ji, J; Li, LX; Liu, W, 2013) |
| "Glaucoma is a leading cause of vision loss and blindness, with increased intraocular pressure (IOP) a prominent risk factor." | ( Amin, J; Brain, C; Elliott, J; Jaffee, B; Lee, W; Long, D; Mainolfi, N; McLaughlin, ME; Powers, J; Sivak, JM, 2013) |
| "Glaucoma is a multifactorial optic neuropathy that can lead to progressive and irreversible loss of vision." | ( Irkec, M; Katsanos, A; Konstas, AG; Mocan, MC; Voudouragkaki, IC, 2013) |
| "Glaucoma is conventionally defined as a chronic optic neuropathy characterized by progressive loss of retinal ganglion cells (RGCs) and optic nerve fibers." | ( Fujita, T; Hirooka, K; Itano, T; Nakamura, T; Nishiyama, A; Nitta, E; Shiraga, F; Tenkumo, K, 2013) |
| "Glaucoma is the leading cause of irreversible blindness worldwide." | ( Mansouri, K; N Weinreb, R; Nuyen, B, 2013) |
| "Glaucoma is a progressive ocular syndrome characterized by degeneration of the optic nerve and irreversible visual field loss." | ( González, MV; Jiménez, AI; Martínez, T; Pañeda, C; Roehl, I; Wright, N, 2014) |
| "Glaucoma is a disease characterized by progressive optic nerve degeneration and is the leading cause of irreversible blindness worldwide." | ( Gupta, A, 2013) |
| "Glaucoma is a progressive neurodegenerative disease of retinal ganglion cells (RGCs) associated with characteristic axon degeneration in the optic nerve." | ( Carroll, RC; Nawy, S; Wang, AL, 2014) |
| "Secondary glaucoma is a serious complication in patients with transthyretin (TTR)-related familial amyloidotic polyneuropathy (FAP)." | ( Ando, Y; Eiki, D; Hara, R; Inoue, T; Kawaji, T; Tanihara, H, 2014) |
| "Glaucoma is a leading cause of irreversible blindness." | ( Jia, Y; Li, Z; Su, W; Zhuo, Y, 2014) |
| "Glaucoma is one of the leading causes of irreversible blindness that is characterized by progressive degeneration of optic nerves and retinal ganglion cells (RGCs)." | ( Harada, C; Harada, T; Kimura, A; Mitamura, Y; Namekata, K; Semba, K, 2014) |
| "Glaucoma is a common sight-threatening condition that is primarily treated by lowering intraocular pressure (IOP)." | ( Chew, SK; Goldberg, I; Skalicky, SE, 2014) |
| "Glaucoma is the second common cause of irreversible blindness worldwide associated with a progressive neurodegenerative disease of retinal ganglion cells (RGC)." | ( Xiong, S; Xu, X, 2014) |
| "Management of glaucoma is difficult with the IOP remaining high in spite of combined medical and surgical management." | ( Ankush, K; George, VP; Muralidhar, R; Vijayalakshmi, P, 2015) |
| "Glaucoma is a chronic neurodegenerative disease characterized by the progressive loss of retinal ganglion cells (RGCs)." | ( Chen, JY; Chen, XY; Gao, F; Gao, FJ; Luo, Y; Nickerson, JM; Sun, XH; Sun, Z; Wang, Y; Wu, JH; Zhang, SH; Zhang, SJ, 2015) |
| "Glaucoma is the main cause of irreversible blindness worldwide." | ( Aliev, G; Averina, OA; Iomdina, EN; Khoroshilova-Maslova, IP; Kovaleva, NA; Reddy, VP; Robustova, OV; Senin, II; Skulachev, MV; Skulachev, VP; Zamyatnin, AA, 2015) |
| "Medical therapy for glaucoma is an economic burden to many patients and should be individualized, according to the socioeconomic status, availability of drugs and the required distance to travel to reach the specialist clinics." | ( Dada, T; Gupta, S; Gupta, V; Kumar, G; Nayak, B; Sihota, R, 2015) |
| "Glaucoma is the second leading cause of blindness worldwide and is characterized by gradual visual impairment owing to progressive loss of retinal ganglion cells (RGCs) and their axons." | ( Aida, T; Harada, T; Namekata, K; Shinagawa, R; Takeda, T; Tanaka, K; Yanagisawa, M, 2015) |
| "Glaucoma is a chronic neurodegenerative disease characterized by loss of retinal ganglion cells, resulting in distinctive changes in the optic nerve head (ONH) and retinal nerve fiber layer." | ( Balasubramanian, M; Belghith, A; Bowd, C; Medeiros, FA; Weinreb, RN; Zangwill, LM, 2015) |
| "Glaucoma is a common eye disease that can lead to irreversible vision loss if left untreated." | ( Fang, Y; Ling, Z; Sun, X, 2015) |
| "Glaucoma is a disease that damages the optic nerve, frequently leading to blindness." | ( Bergkvist, M; Danias, J; Dautriche, CN; Kerr, M; Sharfstein, ST; Stamer, WD; Szymanski, D; Torrejon, KY; Xie, Y, 2015) |
| "Glaucoma is the leading cause of irreversible blindness and is characterized by slow and progressive degeneration of the optic nerve head axons and retinal ganglion cell (RGC), leading to loss of visual function." | ( Alcasid, N; Bushong, E; Ellisman, MH; Ju, S; Ju, WK; Kim, KY; Perkins, GA; Shim, MS; Weinreb, RN, 2015) |
| "HOPE Glaucoma is a 3-year, prospective, parallel-group, pragmatic, single-centred, randomised controlled trial." | ( Fairlamb, H; Forbes, M; Jonker, L, 2015) |
| "Glaucoma is less likely a primary neurodegeneration affecting the CNS and more likely a primary optic neuropathy with secondary effects in the CNS." | ( Danesh-Meyer, HV; Levin, LA, 2015) |
| "Glaucoma is defined as a progressive optic neuropathy and is characterized by an irreversible loss of retinal ganglion cells." | ( Fuchshofer, R; Schneider, M, 2016) |
| "Glaucoma is a vision-threatening disorder characterized by progressive death of retinal ganglion cells (RGCs), although little is known about therapeutic milestones." | ( Chang, SI; Chun, YS; Joo, K; Kim, JC; Kim, KW; Lee, SH; Lim, KS; Min, KM; Oh, DH; Park, SH, 2016) |
| "Glaucoma is one of the leading largely preventable causes of blindness in the world." | ( Abdulaal, M; Al-Haddad, C; Al-Moujahed, A; Ervin, AM, 2015) |
| "Glaucoma is a neurodegenerative disease currently considered a disease involving ocular and visual brain structures." | ( Manni, G; Michelessi, M; Oddone, F; Parisi, V; Quaranta, L; Roberti, G; Tanga, L, 2015) |
| "Glaucoma is a degenerative nerve disorder that results in irreversible blindness." | ( Chen, T; Huo, F; Lv, B; Wei, Y; Xu, Z; Yang, X, 2016) |
| "Glaucoma is the leading cause of irreversible blindness worldwide." | ( Amoozgar, B; Han, Y; Kuo, J; Lin, SC, 2016) |
| "Glaucoma is a progressive neurodegenerative disease, characterized by retinal ganglion cells (RGCs) and axon degeneration." | ( Chen, JL; Fu, HT; Li, CP; Liu, B; Qiu, GZ, 2016) |
| "Glaucoma is commonly treated using eye drops, which is highly inefficient due to rapid clearance (low residence time) from ocular surface." | ( Choksi, HH; Desai, AR; Koli, AR; Lakdawala, DH; Maulvi, FA; Ranch, KM; Shah, DO; Shaikh, AA; Vaidya, RJ; Vyas, BA, 2016) |
| "Glaucoma is a complex neurodegeneration and a leading cause of blindness worldwide." | ( Backstrom, JR; Bond, WS; Hines-Beard, J; Rex, TS, 2016) |
| "Both cataract and glaucoma are significant public health problems." | ( Kunhammad, S; Singh, P, 2014) |
| "Glaucoma is a form of multifactorial ocular neurodegeneration with immensely complex etiology, pathogenesis and pathology." | ( Dada, R; Dada, T; Faiq, MA; Kumar, A; Saluja, D, 2016) |
| "Glaucoma is a disease of the central nervous system affecting retinal ganglion cells (RGCs)." | ( Gossman, CA; Linn, C; Linn, DM, 2016) |
| "Childhood glaucoma is a major therapeutic challenge for pediatric ophthalmologists and glaucoma specialists worldwide." | ( Medsinge, A; Nischal, KK; Samant, M, 2016) |
| "Glaucoma is a neurodegenerative disease and the leading cause of irreversible blindness worldwide." | ( Belforte, N; Cueva Vargas, JL; Di Polo, A, 2016) |
| "Glaucoma is the second leading cause of blindness worldwide, being characterized by progressive optic nerve damage and loss of retinal ganglion cells (RGCs), accompanied by increased inflammatory response involving retinal microglial cells." | ( Agudo-Barriuso, M; Ambrósio, AF; Madeira, MH; Nadal-Nícolas, F; Ortin-Martinez, A; Santiago, AR; Vidal-Sanz, M, 2016) |
| "Glaucoma is the second leading cause of blindness worldwide and its pathogenesis remains unclear." | ( Bilonick, RA; Chan, KC; Conner, IP; Kim, SG; Lawrence, JD; Murphy, MC; Safiullah, Z; Schuman, JS; Teng, CY; Wang, B; Wollstein, G, 2016) |
| "Glaucoma is closely linked with oxidative stress and inflammation, and difficult to treat." | ( Lin, C; Wu, X, 2016) |
| "Glaucoma is a disease in which damage to the optic nerve leads to progressive, irreversible vision loss." | ( Bernier, SM; Krebs, MD; Osmond, M; Pantcheva, MB, 2017) |
| "Glaucoma is an optic neuropathy associated with vascular dysregulation and increased intra-ocular pressure (IOP)." | ( Esteves, R; Freitas, T; Napoleão, P; Neves, C; Saldanha, C; Teixeira, P, 2016) |
| "Considering that glaucoma is a chronic disease that requires long-term medical therapy to preserve vision in patients, it is highly desirable to augment pharmacological bioavailability and govern release profile by tuning the properties of drug delivery carriers." | ( Lai, JY; Luo, LJ, 2017) |
| "Glaucoma is an irreversible and blinding neurodegenerative disease of the eye, and is characterized by progressive loss of retinal ganglion cells (RGCs)." | ( Guo, L; Huang, P; Huang, S; Leung, CK; Lin, Z; Liu, X; Wang, J; Xu, S; Zhong, Y, 2017) |
| "Glaucoma is characterized by a slow and progressive degeneration of the optic nerve, including retinal ganglion cell (RGC) axons in the optic nerve head (ONH), leading to visual impairment." | ( Ju, WK; Kim, KY; Shim, MS, 2017) |
| "Glaucoma is the primary cause of irreversible blindness worldwide associated with high intraocular pressure (IOP)." | ( Liu, Z; Qian, X; Song, H; Wang, W; Zhang, M, 2016) |
| "Glaucoma is a leading cause of irreversible blindness worldwide and the second most common cause of blindness after cataracts." | ( Wang, X; Wu, M; Xu, L, 2017) |
| "Glaucoma is a leading cause of blindness, characterized by retinal ganglion cell (RGC) loss and optic nerve (ON) damage." | ( Bordone, MP; Bosco, A; Dorfman, D; González Fleitas, MF; Pasquini, LA; Rosenstein, RE; Sande, PH, 2017) |
| "Glaucoma is a progressive and irreversible blinding neuropathy that is characterized by the loss of retinal ganglion cells (RGCs)." | ( Bretillon, L; Bron, A; Creuzot-Garcher, C; Ferrerro, A; Gabrielle, PH; Gambert, S; Gendrault, C; Gregoire, S; Lachot, M; Leclere, L; Leger-Charnay, E; Lucchi, G; Martine, L; Masson, E; Pecqueur, D; Truntzer, C; Vannier, A, 2017) |
| "Glaucoma is an optic neuropathy characterized by progressive degeneration of retinal ganglion cells (RGCs) and visual loss." | ( Harada, T; Iwata, T; Kashiwagi, K; Koizumi, S; Namekata, K; Ohno, N; Robaye, B; Shinozaki, Y; Takeda, A, 2017) |
| "Glaucoma is a chronic disease that shares many similarities with other neurodegenerative disorders of the central nervous system." | ( Abbasi, M; Braidy, N; Chick, JM; Chitranshi, N; Cristea, IM; Deng, L; Dheer, Y; Graham, SL; Greco, TM; Gupta, VB; Gupta, VK; Gygi, SP; Haynes, PA; Hone, E; Martins, R; Mirzaei, M; Molloy, MP; Rezaeian, M; Salekdeh, GH; Wall, RV; Wu, Y; You, Y, 2017) |
| "Glaucoma is an incurable optic neuropathy characterized by dysfunction and death of retinal ganglion cells (RGCs)." | ( Bollinger, KE; Mysona, BA; Smith, S; Zhao, J, 2018) |
| "Glaucoma is a multifactorial neurodegenerative disease associated with retinal ganglion cells (RGC) loss." | ( Calpena, AC; Camins, A; Cordeiro, MF; Davis, BM; Egea, MA; Espina, M; Ettcheto, M; García, ML; Guo, L; Ravindran, N; Sánchez-López, E; Silva, AM; Souto, EMB, 2018) |
| "Glaucoma is the leading cause of irreversible blindness worldwide and there is no effective treatment thus far." | ( Deng, S; Huai, G; Liu, Y; Peng, J; Qi, P; Shi, W; Wang, H; Wang, X; Wang, Y; Yang, H, 2018) |
| "Glaucoma is a group of neurodegenerative eye diseases characterized by progressive impairment of visual function due to loss of retinal ganglion cells (RGC)." | ( Guo, L; Huang, P; Huang, S; Li, C; Lin, Z; Liu, X; Shen, X; Xu, X; Zhong, Y, 2018) |
| "Blindness in glaucoma is the result of death of Retinal Ganglion Cells (RGCs) and their axons." | ( Bolton, E; Chou, TH; Musada, GR; Porciatti, V; Romano, GL, 2018) |
| "Glaucoma is a serious eye disease that can lead to loss of vision." | ( Chen, Y; Duan, H; Hou, D; Li, J; Lv, Z; Tao, Q; Tian, S; Yang, F; Zhao, Y; Zhou, Q, 2018) |
| "Glaucoma is hallmarked with the death of retinal neurons in the ganglion cell layer, which results in irreversible vision loss." | ( Cui, H; Jin, Y; Li, Q; Li, R; Sun, X; Zhu, H, 2018) |
| "In India, glaucoma is the third most common cause of blindness, reflecting both its asymptomatic presentation and a lack of knowledge in the general population." | ( Dhabale, V; Khan, MA; Pantola, P; Singh, AK; Tomar, A, 2018) |
| "Glaucoma is characterized by a progressive loss of retinal ganglion cells and their axons, but the underlying biological basis for the accompanying neurodegeneration is not known." | ( Bu, JH; Ellisman, MH; Jeong, SW; Ju, WK; Kim, KY; Nam, HS; Park, TL; Shim, MS; Weinreb, RN, 2018) |
| "Glaucoma is a chronic disease, which is currently treated using frequent high dose applications of an eye drop solution; this method is tedious, and most of patients are non-compliant to it." | ( Desai, AR; Maulvi, FA; Pandya, MM; Ranch, KM; Shah, DO; Shah, SA; Vyas, BA, 2018) |
| "Glaucoma is a prevalent optic neuropathy characterized by the progressive dysfunction and loss of retinal ganglion cells (RGCs) and their optic nerve axons, which leads to irreversible visual field loss." | ( Buys, ES; Sappington, RM; Wareham, LK, 2018) |
| "Glaucoma is the second cause of blindness worldwide." | ( Abdelrehim, RT; Fouda, NH; Habib, BA; Hegazy, DA, 2018) |
| "Glaucoma is the leading cause of irreversible blindness worldwide." | ( Elahi, E; Suri, F; Yazdani, S, 2018) |
| "Glaucoma is an optic neuropathy commonly associated with elevated intraocular pressure (IOP) resulting in progressive loss of retinal ganglion cells (RGCs) and optic nerve degeneration, leading to blindness." | ( Guo, C; Leehy, B; Prasanna, G; Qu, X; Rangaswamy, N; Rice, D; Xiang, C, 2018) |
| "Glaucoma is a common cause of visual impairment in the Veterans Affairs (VA) health care system, but to our knowledge, no data exist concerning tertiary glaucoma care (ie, laser and filtering surgery)." | ( Cockerham, G; Lee, AY; Lee, CS; Lynch, MG; Maa, AY; Pieters, M, 2018) |
| "Outcomes of glaucoma care for the different models of eye care delivery were not analyzed in this study." | ( Cockerham, G; Lee, AY; Lee, CS; Lynch, MG; Maa, AY; Pieters, M, 2018) |
| "Glaucoma is a chronic ophthalmic disease, which has become one of the leading causes to progressive and irreversible blindness." | ( Chen, J; Huang, J; Huang, Y; Huang, Z; Li, Y; Pan, X; Wu, C; Zeng, Y, 2018) |
| "Glaucoma is the first cause of blindness in Europe." | ( Bluwol, E, 2016) |
| "Glaucoma is the leading cause of vision loss and blindness in the world." | ( Chen, Y; Lin, C; Wang, X; Wu, F; Wu, X; Zheng, T, 2019) |
| "Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of irreversible blindness globally and for which intraocular pressure is the only modifiable risk factor." | ( Arranz-Romera, A; Bravo-Osuna, I; Cordeiro, MF; Davis, BM; Esteban-Pérez, S; Guo, L; Herrero-Vanrell, R; Molina-Martínez, IT; Ravindran, N; Shamsher, E, 2019) |
| "Secondary glaucoma is an important cause of visual morbidity." | ( Bhoot, M; Dubey, S; Gandhi, M; Jain, K; Mukherjee, S; Pegu, J; Sharma, N, 2019) |
| "Glaucoma is a common chronic neurodegenerative disease, which could lead to visual loss." | ( Fu, T; Li, L; Qin, J; Shen, J, 2019) |
| "Glaucoma is a neurodegenerative disorder that is generally accepted as the main cause of vision loss." | ( Ren, YL; Wang, C; Wu, J; Zhai, J; Zhou, XY, 2019) |
| "Glaucoma is one of the most common causes of blindness worldwide." | ( Breunig, M; Mietzner, R, 2019) |
| "Glaucoma is the world's second biggest cause of blindness, and patients progressively lose their eyesight." | ( Chen, Q; He, Z; Li, Y; Xi, X; Zeng, Y; Zhao, J, 2019) |
| "Glaucoma is characterized by the death of retinal ganglion cells (RGCs) and visual field defects, and is a leading cause of blindness worldwide." | ( Chen, C; Huang, L; Jia, Y; Jiang, S; Lu, G; Sun, X; Xie, Y, 2019) |
| "Glaucoma is a group of irreversible ocular diseases which result in damage to the optic nerve and vision loss." | ( Bu, R; Feng, S; Ge, Y; Gou, J; He, H; Tang, X; Wang, J; Xu, J; Yin, T; Zhang, A; Zhang, Y, 2019) |
| "Glaucoma is the leading cause of blindness worldwide, resulting from degeneration of retinal ganglion cells (RGCs), which form the optic nerve." | ( Fischer, RA; Roux, AL; Sappington, RM; Wareham, LK, 2019) |
| "Glaucoma is the main cause of irreversible blindness in the world." | ( Kurysheva, NI, 2019) |
| "Since glaucoma is a form of neurodegeneration involving retinal ganglion cells, citicoline may help ameliorate glaucomatous damages in multiple facets." | ( Chan, KC; Faiq, MA; Schuman, JS; Wollstein, G, 2019) |
| "Glaucoma is a main cause of irreversible vision impairment and its prevalence is expected to rise significantly in the near future." | ( Barra, F; Cutolo, CA; Ferrero, S; Ferro Desideri, L; Traverso, CE, 2019) |
| "Glaucoma is the main cause of irreversible blindness in the world." | ( Kurysheva, NI, 2019) |
| "Glaucoma is one of the leading causes of preventable blindness, affecting > 2 million people in the United States." | ( Ahn, JH; Choi, KJ; Jung, WH; Kang, S; Kim, KY; Na, YJ; Nam, HJ; Park, SB, 2019) |
| "Glaucoma is characterized by retinal ganglion cell (RGC) degeneration and is the second leading cause of blindness worldwide." | ( Chan, TTH; Chan, WY; Feng, B; Gao, L; Hobbs, R; Hou, HW; Jiang, X; Lee, TL; Lee, WT; Leung, KS; Li, I; Li, K; Liao, J; Liu, YH; Luk, CS; Mak, HK; Ng, JKW; Ng, TK; Qi, H; Qian, Y; Rudd, JA; Suen, HC, 2019) |
| "Glaucoma is one of the most frequent causes of visual impairment worldwide, and involves selective damage to retinal ganglion cells (RGCs) and their axons." | ( Aranda, ML; Calanni, JS; Chianelli, MS; Devouassoux, JD; Dorfman, D; González Fleitas, MF; Rosenstein, RE, 2020) |
| "Glaucoma is a neurodegenerative eye disease characterized by gradually impaired visual field and irreversible blindness due to retinal ganglion cell (RGC) loss." | ( Guo, L; Huang, P; Huang, S; Lin, Z; Liu, X; Shen, X; Yu, H; Zhong, Y, 2019) |
| "Glaucoma is a multifactorial blinding disease with a major inflammatory component ultimately leading to apoptotic retinal ganglion cell (RGC) death." | ( Bagnoli, P; Cammalleri, M; Dal Monte, M; Locri, F; Rusciano, D, 2019) |
| "Glaucoma is an irreversible eye disease caused by the optic nerve injury." | ( Chen, C; Chen, Q; Duan, X; Ouyang, P; Zhao, R; Zhu, C; Zou, B, 2019) |
| "Glaucoma is a progressive neurodegenerative process affecting the retinal ganglion cells (RGCs) and the optic nerve." | ( Bargoud, AR; Cui, QN; Dunaief, JL; Ross, AG; Song, Y, 2020) |
| "Glaucoma is an optic neuropathy and involves the progressive degeneration of retinal ganglion cells (RGCs), which leads to blindness in patients." | ( Houck, JA; Johnson, GC; MacLean, PS; Nagaraj, RH; Nahomi, RB; Nam, MH; Pantcheva, MB; Rakete, S; Rankenberg, J; Stankowska, DL, 2020) |
| "Glaucoma is characterized by apoptotic loss of retinal ganglion cells (RGCs) and loss of visual fields and is a leading cause of irreversible blindness." | ( Agarwal, P; Agarwal, R; Iezhitsa, I; Ismail, NM; Nor Arfuzir, NN, 2020) |
| "Glaucoma is the main cause of irreversible blindness in the world." | ( Kurysheva, NI, 2020) |
| "Glaucoma is a disease that causes irreversible blindness." | ( Huang, ZJ; Mao, YJ; Wu, JB; Yang, ZQ; Zhang, YH, 2020) |
| "Glaucoma is a group of optic neuropathies associated with aging and sensitivity to intraocular pressure (IOP)." | ( Calkins, DJ; Carlson, BJ; Collyer, JW; Formichella, CR; Ghose, P; Lambert, WS; Pasini, S, 2020) |
| "Glaucoma is a neurodegenerative disease, our study aimed to evaluate the potential effects of Palmitoylethanolamide (PEA) supplementation on RGCs function by PERG examination, and to record effects on intraocular pressure, visual field and quality of life." | ( Bettio, F; Bianchi, PE; Briola, A; Lumini, C; Mirabile, A; Pasinetti, GM; Paviglianiti, A; Picasso, E; Rossi, GCM; Ruberto, G; Scudeller, L, 2020) |
| "Glaucoma is optic neuropathy that is characterized by progressive neurodegeneration of the retinal ganglion cells (RGCs) and axons." | ( Kiuchi, Y; Ko, JA; Komatsu, K; Okumichi, H, 2021) |
| "Glaucoma is a progressive optic neuropathy that has become the most common cause of irreversible blindness worldwide." | ( Deng, C; Hu, P; Li, N; Li, X; Ma, F; Pang, Y; Shao, A; Song, Y; Wang, F; Zhang, X, 2020) |
| "However, glaucoma is still a foreign word to our community despite the high prevalence." | ( Al-Naggar, RA; Al-Rashidi, RR; Alshaikhli, H; Saleh, B, 2020) |
| "Glaucoma is a neurodegenerative disease characterized by loss of retinal ganglion cells (RGCs), the output neurons of the retina." | ( Howell, GR; Libby, RT; Marola, OJ; Syc-Mazurek, SB, 2020) |
| "glaucoma is the leading cause of irreversible blindness all over the world." | ( Aiello, F; Bagetta, G; Cesareo, M; Corasaniti, MT; Nucci, C; Scuteri, D; Tonin, P, 2020) |
| "Glaucoma is a progressive chronic retinal degenerative disease and a leading cause of global irreversible blindness, characterized by optic nerve damage and retinal ganglion cell (RGC) death." | ( Aires, ID; Ambrósio, AF; Boia, R; Ferreira-Silva, J; Santiago, AR, 2020) |
| "Primary open-angle glaucoma is a major cause of irreversible blindness in all countries of the world." | ( Korsakova, NV, 2020) |
| "Glaucoma is the most common cause of irreversible blindness worldwide." | ( Khawaja, AP; Stein, JD; Weizer, JS, 2021) |
| "Glaucoma is a chronic progressive optic neuropathy, characterized by damage to the optic nerve and retinal nerve fiber layer, that can lead to permanent loss of peripheral or central vision." | ( Khawaja, AP; Stein, JD; Weizer, JS, 2021) |
| "Glaucoma is the second leading cause of irreversible blindness worldwide." | ( Bartz-Schmidt, KU; de Vries, JW; Frößl, K; Gruszka, A; Herrmann, A; Hurst, J; Löscher, M; Schnichels, S; Spitzer, MS; Ullah, S, 2021) |
| "Glaucoma is a degenerative optic neuropathy characterized by increased intraocular pressure that if untreated can result in blindness." | ( Akhlaghi, SP; Allemandi, DA; Bessone, CDV; Loh, W; Quinteros, DA; Tártara, LI, 2021) |
| "Glaucoma is a neurodegenerative disease that affects eye structures and brain areas related to the visual system." | ( Calabró, V; Evelson, PA; Ferreira, SM; Hvozda Arana, AG; Lasagni Vitar, RM; Lerner, SF; Marchini, T; Reides, CG, 2021) |
| "Glaucoma is a blindness-causing disease that involves selective damage to retinal ganglion cells (RGCs) and their axons." | ( Aranda, ML; Calanni, JS; Devouassoux, J; Dieguez, HH; Dorfman, D; González Fleitas, MF; Iaquinandi, A; Rosenstein, RE; Sande, PH, 2021) |
| "Glaucoma is an advanced nerve disorder described by the deterioration of axon and RGCs." | ( Ji, Y; Liu, Y; Wu, X, 2021) |
| "Glaucoma is a neurodegenerative disease that causes progressive, irreversible vision loss." | ( Chan, KC; Conner, IP; Faiq, MA; Ho, LC; Leung, CK; Murphy, MC; Schuman, JS; Sims, JR; van der Merwe, Y; Wollstein, G; Yang, XL; Yu, Y, 2021) |
| "Siderotic glaucoma is a rare and challenging clinical scenario caused by a retained iron intraocular foreign body (IOFB), which results in irreversible vision loss." | ( Gawas, L; Padhi, TR; Sahoo, N, 2021) |
| "Glaucoma is a progressive neurodegenerative disease which constitutes the main frequent cause of irreversible blindness." | ( Lecarpentier, Y; Vallée, A; Vallée, JN, 2021) |
| "Glaucoma is a common neurodegenerative disease in which neuronal levels of NAD decline." | ( Brautaset, R; Burgess, RW; Cimaglia, G; Crowston, JG; Domínguez-Vicent, A; Ellis, SA; Fuerst, PG; Jöe, M; Jóhannesson, G; Kokkali, E; Kolko, M; Lardner, E; Morgan, JE; Otmani, A; Rho, S; Sun, S; Tribble, JR; Venkataraman, AP; Vohra, R; Votruba, M; Williams, PA, 2021) |
| "Glaucoma is a common progressive optic neuropathy that results in visual field defects and can lead to irreversible blindness." | ( Eivers, SB; O'Brien, CJ; O'Regan, A, 2021) |
| "Uveitic glaucoma is aggressive, with high likelihood of requiring surgical management and high risk of central vision loss." | ( Bennett, S; Chew, S; Ma, T; Niederer, RL; Sims, JL, 2022) |
| "Steroid-induced glaucoma is a severe pathological condition, sustained by a rapidly progressive increase in intraocular pressure (IOP), which is diagnosed in a subset of subjects who adhere to a glucocorticoid (GC)-based therapy." | ( Coletta, M; Manni, G; Oddone, F; Sbardella, D; Tundo, GR, 2021) |
| "Glaucoma is the leading cause of irreversible blindness worldwide." | ( Chau, KY; Garway-Heath, DF; Lascaratos, G; Petriti, B; Williams, PA, 2021) |
| "Primary open-angle glaucoma is associated with elevated intraocular pressure (IOP) that damages the optic nerve and leads to gradual vision loss." | ( Gong, H; Johnson, M; Li, G; Perkumas, KM; Ren, R; Scott, EA; Stack, T; Stamer, WD; Vahabikashi, A; Vincent, MP, 2021) |
| "Glaucoma is the second leading cause of blindness globally, and the recent application of Adenosine and its derivatives has shown the critical role of the adenosine pathway in its pathophysiology." | ( Arasteh, A; Ghorbani, A; Hallaj, S; Jadidi-Niaragh, F; Lee, D; Mirza-Aghazadeh-Attari, M, 2021) |
| "Glaucoma is a leading cause of irreversible blindness worldwide, and increased intraocular pressure (IOP) is a major risk factor." | ( Elwood, BW; Godwin, CR; Gramlich, OW; Kuehn, MH; Wadkins, D, 2021) |
| "Glaucoma is a progressive optic neuropathy with characteristic changes to the optic nerve head and the visual field (VF)." | ( Brusini, P; Chauhan, BC; Crabb, DP; Fenolland, JR; Fogagnolo, P; Giraud, JM; Montesano, G; Oddone, F; Rossetti, LM; Rui, C, 2021) |
| "Glaucoma is a chronic eye disease characterized by elevated intraocular pressure (IOP) which causes severe complications to the eyes and may lead to vision loss." | ( Ahmed, KA; El-Feky, YA; El-Telbany, DFA; El-Telbany, RFA; Fares, AR; Zayed, G, 2021) |
| "Glaucoma is an ophthalmic disease that is characterized by elevated intraocular pressure (IOP)." | ( Huang, J; Ma, F; Pang, Y; Song, Y; Wang, F; Wang, X; Wang, Y; Wu, B; Zhang, W; Zhang, X; Zhu, Z, 2021) |
| "Glaucoma is a multifactorial neuropathy characterized by increased intraocular pressure (IOP), and it is the second leading cause of blindness worldwide after cataracts." | ( Lanzi, C; Lucarini, L; Masini, E; Sgambellone, S, 2021) |
| "Glaucoma is a multifactorial disease resulting in progressive vision loss due to retinal ganglion cell (RGC) dysfunction and death." | ( Gramlich, OW; Kuehn, MH; Shestopalov, VI; Spurlock, M, 2021) |
| "Glaucoma is the leading cause of irreversible blindness globally." | ( Hurley, DJ; Irnaten, M; O'Brien, C, 2021) |
| "Glaucoma is a major cause of sight loss worldwide, with the highest regional prevalence and incidence reported in Africa." | ( Burton, MJ; da Gama, V; Fopoussi, N; Gazzard, G; Knoll, KM; Macha, E; Macleod, D; Makupa, A; Makupa, WU; Marques, AP; Matayan, E; Matsinhe, C; Mbishi, S; Monjane, M; Mulobuana, FA; Muna, E; Ncheda, AJ; Philippin, H; Shah, P, 2021) |
| "Cataract and glaucoma are the major causes of severe visual loss and blindness in older adults." | ( Tanito, M, 2021) |
| "Glaucoma is characterized by progressive damage of the retinal ganglion cells (RGCs), resulting in irreversible vision loss." | ( Hsu, E; Kadhim, S; Kumar, U; Padania, S; Somvanshi, RK; Zou, S, 2022) |
| "Glaucoma is the second leading cause of blindness in India." | ( Ariga, M; Choudhry, RM; Dubey, S; George, R; Murthy, GJ; Panday, M; Parikh, R; Sarma, P; Singh, M, 2022) |
| "Currently, glaucoma is managed by frequent instillation of bimatoprost eye drop therapy, which showed very poor ocular bioavailability." | ( Chengquan, L; Chunfang, W; Fagang, J; Jun, J; Xiaojie, H; Xinghua, W, 2021) |
| "Glaucoma is a neurodegenerative disease that leads to blindness, and lowering intraocular pressure (IOP) is very important in glaucoma treatment." | ( Aoshima, K; Hara, H; Inagaki, S; Iwata, Y; Morozumi, W; Nakamura, S; Shimazawa, M; Takagi, Y, 2022) |
| "Glaucoma is a leading cause of irreversible blindness worldwide and is characterized by progressive loss of visual function and retinal ganglion cells (RGC)." | ( Dattilo, M; Douglass, A; Feola, AJ, 2023) |
| "Glaucoma is a leading cause of global irreversible blindness, and characterized by the progressive loss of retinal ganglion cells (RGCs)." | ( Cai, JY; Du, HY; Jian, YL; Li, JL; Luo, H; Wang, R; Xie, XY; Yan, R, 2021) |
| "Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness." | ( Belamkar, A; Ciulla, TA; Harris, A; Oddone, F; Siesky, B; Verticchio Vercellin, A; Zukerman, R, 2022) |
| "Glaucoma is a leading cause of irreversible blindness and ripasudil was the first Rho kinase inhibitor approved as antiglaucoma medication." | ( Kakuda, T; Kanno, T; Kurihara, Y; Sano, T; Tanihara, H, 2022) |
| "Glaucoma is the leading cause of irreversible vision loss worldwide, and reduction of intraocular pressure (IOP) is the only factor that can be interfered to delay disease progression." | ( Hong, J; Huang, C; Sun, J; Sun, X; Xu, J; Zhang, Z; Zhao, Y, 2022) |
| "Glaucoma is one of the leading causes of loss of vision." | ( Das, S; Giri, L; Majumdar, S; Saha, D, 2022) |
| "Glaucoma is a heterogeneous group of progressive optic neurodegenerative." | ( Bui, AD; Chen, C; Doan, T; Han, Y; Hinterwirth, A; Ma, P; Xie, Q; Yonamine, S; Zhao, M; Zhong, L, 2022) |
| "Glaucoma is the second leading cause of global blindness." | ( Chen, Y; Deng, B; Fu, J; He, C; Li, A; Li, B; Liu, D; Lu, F; Shuai, P; Zhang, G; Zhang, R, 2022) |
| "Glaucoma is one of the leading causes of blindness." | ( Abdelfattah, EA; El-Kamel, A; El-Moslemany, RM; Mehanna, RA; Radwan, SE; Thabet, EH, 2022) |
| "Glaucoma is treated by frequent instillation of 0." | ( Li, H; Xu, Y, 2022) |
| "Glaucoma is an optic neuropathy disorder marked by progressive degeneration of the retinal ganglion cells (RGC)." | ( Mhatre, S; Opere, CA; Singh, S, 2022) |
| "Glaucoma is a neurodegenerative disease of visual system characterized by gradual loss of retinal ganglion cells (RGC)." | ( Chen, J; Huang, P; Huang, S; Liu, X; Shen, X; Wang, J; Yu, H; Zhong, Y, 2022) |
| "Glaucoma is a common eye disease and a major cause of blindness." | ( Chen, L; Wu, R, 2022) |
| "Glaucoma is a neurodegenerative disorder caused by the death of retinal ganglion cells (RGCs)." | ( Brahma, MM; Goshima, Y; Harada, T; Namekata, K; Ohshima, T; Takahashi, K, 2022) |
| "Glaucoma is a collection of irreversible optic neuropathies which, if left untreated, lead to severe visual field loss." | ( Pietris, J, 2022) |
| "Glaucoma is a serious complication associated with this disorder." | ( Haripriya, A; Mohan, N; Rajendran, A; Venkataraman, P, 2022) |
| "Glaucoma is the leading cause of irreversible blindness due to increased intraocular pressure (IOP) in the eye." | ( Chen, CC; Cheng, YT; Chou, YL; Hsu, YL; Huang, HY; Huang, YL; Hung, JH; Lin, JY; Ng, IS; Sun, SY; Tsai, RH; Wang, LA; Yu, YC, 2022) |
| "Senile glaucoma is a common ophthalmological disease in the elderly." | ( Chen, F; Xia, X; Yan, A; Zhou, J, 2022) |
| "Glaucoma is an optic neuropathy and is currently one of the most common diseases that leads to irreversible blindness." | ( Harada, K; Hide, I; Kiuchi, Y; Masuda, S; Sakai, N; Shiraki, H; Sotomaru, Y; Tanaka, S, 2022) |
| "Glaucoma is a common neurodegenerative blinding disease that is closely associated with chronic biomechanical strain at the optic nerve head (ONH)." | ( Chan, D; Flanagan, JG; Guo, X; Sigal, IA; Sivak, JM; Vicic, N, 2022) |
| "Glaucoma is a progressive optic neuropathy characterized by the neurodegeneration of the retinal ganglion cells (RGCs) resulting in irreversible visual impairment and eventual blindness." | ( Armstrong, J; Choudhary, A; Criddle, DN; Czanner, G; McDonagh, B; Vallabh, NA; Willoughby, CE, 2022) |
| "Glaucoma is the main cause of irreversible blindness in the world." | ( Kurysheva, NI, 2022) |
| "Glaucoma is the leading cause of irreversible blindness in the world." | ( Gu, M; Guo, W; Huang, L; Liu, Y; Sun, H; Wang, N; Wu, Y; Xu, L; Yang, Y, 2022) |
| "Both uveitis and glaucoma are common in domestic animals and humans, and many similarities exist in pathogenesis, genetics, and response to therapy." | ( Gilger, BC, 2022) |
| "Glaucoma is the leading cause of irreversible blindness worldwide and is often undetected in resource-limited settings." | ( McClain, IJ; Rooney, DM; Tabin, GC, 2022) |
| "Glaucoma is a neurodegenerative disease that causes irreversible blindness due to loss of retinal ganglion cells (RGCs) and their axons." | ( Kuchtey, J; Kuchtey, RW; Wu, HJ, 2022) |
| "Glaucoma is the leading cause of irreversible blindness." | ( An, Y; Ding, L; Li, H; Song, S; Wang, C; Xia, X; Xia, Z; Zhou, X, 2022) |
| "Glaucoma is one of the irreversible ocular diseases that can cause vision loss in some serious cases." | ( Choi, H; Hahn, SK; Hong, SH; Jeong, SH; Joo, CK; Kim, TY; Mok, JW; Shin, S, 2022) |
| "Glaucoma is a worldwide leading cause of irreversible blindness." | ( Beisel, A; Berman, L; Bollinger, K; De Greef, O; Mysona, BA; Patel, PA; Smith, SB; Zhao, J, 2023) |
| "Glaucoma is a worldwide leading cause of irreversible blindness." | ( Beisel, A; Berman, L; Bollinger, K; De Greef, O; Mysona, BA; Patel, PA; Smith, SB; Zhao, J, 2023) |
| "Glaucoma is a worldwide leading cause of irreversible blindness." | ( Beisel, A; Berman, L; Bollinger, K; De Greef, O; Mysona, BA; Patel, PA; Smith, SB; Zhao, J, 2023) |
| "Glaucoma is a progressive age-related disease of the visual system and the leading cause of irreversible blindness worldwide." | ( Haider, AA; Rex, TS; Wareham, LK, 2022) |
| "Glaucoma is a progressive age-related disease of the visual system and the leading cause of irreversible blindness worldwide." | ( Haider, AA; Rex, TS; Wareham, LK, 2022) |
| "Glaucoma is a progressive age-related disease of the visual system and the leading cause of irreversible blindness worldwide." | ( Haider, AA; Rex, TS; Wareham, LK, 2022) |
| "Glaucoma is a group of eye diseases consisting of optic nerve damage with corresponding loss of field vision and blindness." | ( Andreozzi, G; Calderone, V; Caliendo, G; Citi, V; Corvino, A; Fiorino, F; Frecentese, F; Magli, E; Martelli, A; Perissutti, E; Piragine, E; Santagada, V; Severino, B; Sparaco, R, 2022) |
| "Glaucoma is a group of eye diseases consisting of optic nerve damage with corresponding loss of field vision and blindness." | ( Andreozzi, G; Calderone, V; Caliendo, G; Citi, V; Corvino, A; Fiorino, F; Frecentese, F; Magli, E; Martelli, A; Perissutti, E; Piragine, E; Santagada, V; Severino, B; Sparaco, R, 2022) |
| "Glaucoma is a group of eye diseases consisting of optic nerve damage with corresponding loss of field vision and blindness." | ( Andreozzi, G; Calderone, V; Caliendo, G; Citi, V; Corvino, A; Fiorino, F; Frecentese, F; Magli, E; Martelli, A; Perissutti, E; Piragine, E; Santagada, V; Severino, B; Sparaco, R, 2022) |
| "Secondary glaucomas are more common than primary/congenital glaucomas." | ( Kavitha, S; Odayappan, A; Parab, A; Venkatesh, R, 2022) |
| "Secondary glaucomas are more common than primary/congenital glaucomas." | ( Kavitha, S; Odayappan, A; Parab, A; Venkatesh, R, 2022) |
| "Pediatric glaucoma is a constellation of challenging ophthalmic conditions that, left untreated, can result in irreversible vision loss." | ( Vanderveen, DK; Young, AK, 2023) |
| "Pediatric glaucoma is a constellation of challenging ophthalmic conditions that, left untreated, can result in irreversible vision loss." | ( Vanderveen, DK; Young, AK, 2023) |
| "Glaucoma is a chronic eye disease in which the pressure inside the eye increases and leads to damage to the optic nerve, and eventually causes blindness." | ( Bigdeli, A; Feghhi, M; Makhmalzadeh, BS; SoleimaniBiatiani, E, 2023) |
| "Glaucoma is a chronic eye disease in which the pressure inside the eye increases and leads to damage to the optic nerve, and eventually causes blindness." | ( Bigdeli, A; Feghhi, M; Makhmalzadeh, BS; SoleimaniBiatiani, E, 2023) |
| "Glaucoma is the leading cause of irreversible blindness worldwide, characterized by progressive vision loss due to the selective damage to retinal ganglion cells (RGCs) and their axons." | ( Ji, D; Li, H; Liang, G; Liang, Z; Rong, R; Xia, X; Xiao, H; You, M; Zeng, Z; Zhou, X, 2022) |
| "Glaucoma is the leading cause of irreversible blindness worldwide, characterized by progressive vision loss due to the selective damage to retinal ganglion cells (RGCs) and their axons." | ( Ji, D; Li, H; Liang, G; Liang, Z; Rong, R; Xia, X; Xiao, H; You, M; Zeng, Z; Zhou, X, 2022) |
| "Glaucoma is a chronic disease that requires long-term adherence to treatment." | ( Han, X; Hou, D; Hu, J; Ke, Y; Li, H; Li, W; Lin, H; Liu, H; Rupenthal, ID; Yang, F; Ye, J; Zhao, Y, 2022) |
| "Glaucoma is a chronic disease that requires long-term adherence to treatment." | ( Han, X; Hou, D; Hu, J; Ke, Y; Li, H; Li, W; Lin, H; Liu, H; Rupenthal, ID; Yang, F; Ye, J; Zhao, Y, 2022) |
| "Glaucoma is a complex neurodegenerative disease characterized by optic nerve damage and apoptotic retinal ganglion cell (RGC) death, and is the leading cause of irreversible blindness worldwide." | ( Basavarajappa, D; Chitranshi, N; Graham, SL; Gupta, V; Klistorner, A; Mirshahvaladi, SSO; Mirzaei, M; Palanivel, V; Wall, RV; You, Y, 2023) |
| "Glaucoma is a complex neurodegenerative disease characterized by optic nerve damage and apoptotic retinal ganglion cell (RGC) death, and is the leading cause of irreversible blindness worldwide." | ( Basavarajappa, D; Chitranshi, N; Graham, SL; Gupta, V; Klistorner, A; Mirshahvaladi, SSO; Mirzaei, M; Palanivel, V; Wall, RV; You, Y, 2023) |
| "Glaucoma is one of the most common causes of treatable visual impairment in the developed world, affecting approximately 64 million people worldwide, some of whom will be bilaterally blind from irreversible optic nerve damage." | ( Irnaten, M; O'Brien, CJ, 2023) |
| "Glaucoma is the leading cause of irreversible blindness and is a major health and economic burden." | ( Hagström, A; Jusseaume, K; Lardner, E; Stålhammar, G; Tribble, JR; Williams, PA; Wong, RC, 2023) |
| "Glaucoma is the leading cause of irreversible blindness, and its treatment is attracting widespread attention." | ( Bai, H; Li, J; Ma, A; Ma, Y; Xiao, S; Zhang, B; Zhou, H, 2023) |
| "Glaucoma is often associated with elevated intraocular pressure (IOP), generally due to obstruction of aqueous humor outflow within the trabecular meshwork (TM)." | ( Cepurna, WO; Chan, F; Ing, E; Keller, KE; Lozano, DC; Morrison, JC; Yang, YF, 2023) |
| "Glaucoma is the major cause of irreversible blindness in the world characterized by progressive retinal neurodegeneration, in which local inflammation in retina is involved in persistent loss of retinal ganglion cells (RGCs)." | ( Gu, M; Guo, W; Huang, L; Liu, Y; Sun, H; Wang, N; Wu, Y; Xu, L; Yang, Y, 2023) |
| "Glaucoma is a chronic disease that requires lifelong treatment, whereas, discomfort caused by frequent medication may affect the quality of life." | ( Gou, J; He, H; Long, L; Ning, Y; Tang, X; Wang, Z; Xiong, J; Yin, T; Zhang, Y; Zhao, J, 2023) |
| "Glaucoma is an optic neuropathy characterized by death of retinal ganglion cells (RGCs), which leads to progressive visual field loss and may result in blindness." | ( Costa, VP; Goulart Nacácio E Silva, S; Occhiutto, ML, 2023) |
| "Secondary glaucoma is a potentially blinding ocular complication with a pathogenesis that includes complicated immunological factors, intraocular inflammation, different types of angle abnormalities, and the administration of steroids, which may result in physical discomfort and visual impairment." | ( Chen, M; Ke, W; Li, Y; Wang, K; Yang, Y; Ye, Z, 2023) |
| "Glaucoma is reportedly associated with asymmetric dimethylarginine (ADMA) and circadian blood pressure (BP) variability, including night-time SBP." | ( Jimura, H; Miyata, K; Obayashi, K; Ogata, N; Saeki, K; Yoshikawa, T, 2023) |
| "Glaucoma is the leading cause of irreversible vision loss worldwide, and multiple risk factors influence its pathogenesis and progression, including age, increased intraocular pressure (IOP), low-grade inflammation, oxidative stress, and ocular blood flow deficits." | ( Liu, Y; Wei, X; Xu, Z; Ye, H, 2023) |
| "Glaucoma is a common neurodegenerative disorder characterized by retinal ganglion cell death, astrocyte reactivity in the optic nerve, and vision loss." | ( Jakobs, TC; Li, S, 2023) |
| "Glaucoma is a major cause of irreversible blindness worldwide." | ( Kavitha, S; Subbulakshmi, S; Venkatesh, R, 2023) |
| "Glaucoma is a leading cause of blindness worldwide." | ( Hirooka, K; Kiuchi, Y; Ko, JA; Komatsu, K; Kondo, S; Minamoto, A; Okumichi, H, 2023) |
| "Glaucoma is the leading cause of irreversible blindness, and the loss of retinal ganglion cells (RGCs) is the most important pathological feature." | ( A, L; Chen, S; Gao, H; Xie, J; Xu, H; Yin, ZQ, 2023) |
| "Glaucoma is an age-related neurodegenerative disease of the visual system, affecting both the eye and the brain." | ( Bang, JW; Chan, KC; Parra, C; Schuman, JS; Wollstein, G; Yu, K, 2023) |
| "Glaucoma is one of the leading causes of irreversible blindness." | ( Hedengran, A; Kolko, M, 2023) |
| "Glaucoma is a leading cause of permanent blindness worldwide and is characterized by neurodegeneration linked to progressive retinal ganglion cell (RGC) death, axonal damage, and neuroinflammation." | ( Basavarajappa, D; Chitranshi, N; Graham, SL; Gupta, V; Klistorner, A; Mirzaei, M; Palanivel, V; Vander Wall, R; Viswanathan, D; You, Y, 2023) |
| "Glaucoma is the third leading cause of blindness worldwide and is primarily characterized by elevated intraocular pressure (IOP)." | ( Guo, X; Huang, J; Li, Q; Li, X; Liu, H; Liu, X; Lu, Y; Luo, L; Shi, Y; Wang, S; You, J; Zhang, J; Zhou, H, 2023) |
| "Glaucoma is a leading cause of blindness worldwide, with elevated intraocular pressure being a major risk factor for its development and progression." | ( Cwiklik, L; Daull, P; Garrigue, JS; Olżyńska, A; Riedlová, K; Saija, MC; Vazdar, K, 2023) |
| "Myopia and glaucoma are two common ocular diseases that pose significant health and economic burdens to patients, their families, and society." | ( Liu, K; Zhu, TY, 2023) |
| "Glaucoma is a leading cause of irreversible blindness worldwide." | ( Feng, Y; Liu, H; Mercieca, K; Prinz, J; Prokosch, V; Wang, M; Wang, X, 2023) |
| "Glaucoma is a leading cause of irreversible blindness worldwide." | ( Fuest, M; Liu, H; Migliorini, F; Prinz, J; Prokosch, V; Walter, P, 2023) |
| "Glaucoma is a neurodegenerative disease characterized by progressive excavation of the optic nerve head, retinal axonal injury and corresponding vision loss that affects millions of people on a global scale." | ( Boccaccini, A; Bocedi, A; Carnevale, C; Cavaterra, D; Graziani, G; Lacal, PM; Manni, G; Marini, S; Sbardella, D; Tanga, L; Tundo, GR, 2023) |
| "Glaucoma is a leading cause of the global prevalence of irreversible blindness." | ( Nagstrup, AH, 2023) |
| Excerpt | Reference |
|---|
| "Medical treatment of the glaucoma was successful." | ( Leib, ML; Little, JM; Saheb, NN, 1979) |
| "The practical implications for treatment of glaucoma require longer-term investigations some of which are in progress." | ( Cullen, PM; Elliot, MJ; Phillips, CI, 1975) |
| "Eleven patients with previously untreated glaucoma of one eye were given metoprolol, 50 mg x 3 for one day." | ( Alm, A; Eckström, C; Ohman, L; Wickström, CP, 1979) |
| "For adequate treatment of acute glaucoma only 20% of commonly used Diamoxdosis is requested to reach comparable pressure release two hours later." | ( Bleckmann, H, 1976) |
| "The aim of all treatment for glaucoma is to lower intra-ocular pressure." | ( Alm, A; Berggren, L, 1992) |
| "The author presents conservative treatment of glaucoma." | ( Tost, M, 1989) |
| "Such an agent would be useful in the treatment of glaucoma." | ( Anderson, PS; Baldwin, JJ; Best, DB; Christy, ME; Freedman, MB; Gautheron, P; Graham, SL; Habecker, CN; Hoffman, JM; Shepard, KL, 1989) |
| "Presented are the results of surgical treatment glaucoma in congenital aniridia (10 eyes), in the syndrome of closed anterior chamber (7 eyes), in Sturge-Weber's syndrome (7 eyes) in marfan's disease (2 eyes), in Lowe's disease (2 eyes) and Recklinghausen's disease (1 eye)." | ( Koraszewska-Matuszewska, B; Samochowiec-Donocik, E, 1989) |
| "Long-term treatment of glaucoma and ocular hypertension is being carried out increasingly by topical application of beta-adrenergic drugs." | ( Noack, E, 1986) |
| "Three laser techniques for the treatment of glaucoma are described." | ( Kitazawa, Y; Mishima, S; Shirato, S, 1985) |
| "All cases of surgically treated neovascular glaucoma were reviewed." | ( Allen, RC; Bellows, AR; Hutchinson, BT; Murphy, SD, 1982) |
| "In 10 patients with previously untreated glaucoma intraocular pressure (IOP) responses and plasma concentrations were determined for increasing doses of acetazolamide." | ( Alm, A; Berggren, L; Hartvig, P; Roosdorp, M, 1982) |
| "In eyes with treated exfoliation glaucoma pilocarpine and phenylephrine combined produced a significant increase in pressure and decrease in outflow because of pigment release." | ( Mapstone, R, 1981) |
| "Generally, there are adequate to treat glaucoma without perimetric changes, while treatment of glaucoma with functional defects requires their association with miotics." | ( Collignon-Brach, J; Weekers, R, 1981) |
| "This raises new possibilities in the treatment of glaucomatous damage to the retina, by the potential interruptibility of a program for neuronal death." | ( Garcia-Valenzuela, E; Shareef, S; Sharma, SC; Walsh, J, 1995) |
| "In 35 of the 56 treated glaucoma patients the thresholds improved more than 0." | ( Martin-Boglind, L; Wanger, P, 1994) |
| "Historically, treatment for glaucoma has been based on lowering intraocular pressure." | ( Azuma, I, 1993) |
| "Following treatment with antiglaucomatous medication, the average intraocular pressure decreased from 31." | ( Krieglstein, GK; Mietz, H, 1994) |
| "14 eyes of 14 patients with medically untreatable glaucoma and extremely bad surgical prognosis because of young age, secondary glaucomas or following previous surgery were treated by means of goniotrephination with a scleral flap and a fornix-based conjunctival flap." | ( Grehn, F; Pfeiffer, N, 1993) |
| "Twenty-nine of these were treated for glaucoma and eight followed for ocular hypertension without treatment." | ( Martin, L; Wanger, P, 1998) |
| "As a first-line agent for the treatment of glaucoma and ocular hypertension, brimonidine has clinical effectiveness equivalent to timolol, but with less chronotropic effect on the heart." | ( Javitt, JC; Schiffman, RM, 2000) |
| "She had been treated for glaucoma, blepharoconjunctivitis, dacryocystitis, and lacrimal canalicular obstruction for two years with topical administration including 0." | ( Arai, Y; Kubo, M; Nakazawa, M; Sakuraba, T, 2001) |
| "He was treated with anti-glaucoma medications." | ( Anand, R; Athmanathan, S; Mandal, AK; Rao, GN; Sridhar, MS, 2001) |
| "Development of citicoline as a treatment for glaucoma is indicated." | ( Grieb, P; Rejdak, R, 2002) |
| "It is used in the treatment of glaucoma to lower the intraocular pressure." | ( Banditt, P; Martens-Lobenhoffer, J, 2002) |
| "Newly treated glaucoma patients younger than 65 years of age were selected based on an initial glaucoma medication fill during a 12-month period." | ( Bookhart, BK; Dasgupta, S; Mozaffari, E; Oates, V; Schwartz, GF; Vaziri, B, 2002) |
| "Latanoprost, used clinically in the treatment of glaucoma, induces growth of lashes and ancillary hairs around the eyelids." | ( Albert, DM; Johnstone, MA, 2002) |
| "No experience exists for treatment of glaucoma with latanoprost in childhood." | ( Schlote, T, 2002) |
| "Despite treatment, glaucoma patients may still suffer vision loss because of inadequate control of intraocular pressure or late presentation." | ( Phelan, P, 2002) |
| "With the newer prostaglandin treatments for glaucoma being available, nurses may usefully and safely be able to prescribe first-line treatments for glaucoma." | ( Birch, MK; Griffiths, PG; Johnson, ZK, 2003) |
| "ecothiophate) applied as eye drops to treat glaucoma in the 1960's." | ( Collison, DJ; Duncan, G, 2003) |
| "The most useful miotic in the treatment of glaucoma is still pilocarpine." | ( McBAIN, EH, 1954) |
| "Thus, to effectively treat glaucoma it may be necessary to counteract the ischaemic-like insult to the region of the optic nerve head." | ( Casson, R; Chidlow, G; DeSantis, L; Osborne, NN; Schmidt, KG; Wood, JP, 2004) |
| "In the initial treatment of glaucoma, prostaglandin analogs have indisputable advantages: better efficacy than timolol--particularly for inducing low or even very low IOP--but also their possible use in normotensive glaucoma, posology of a single instillation per day, and no systemic effects." | ( Baudouin, C, 2004) |
| "Trabeculectomy is performed as a treatment for glaucoma to lower the intraocular pressure (IOP)." | ( Indar, A; Wilkins, M; Wormald, R, 2005) |
| "To determine whether memantine as a treatment for glaucoma prevents neuron shrinkage in the lateral geniculate nucleus, the major target for retinal ganglion cells." | ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "Memantine- and vehicle-treated glaucoma groups were compared using t tests and analysis of covariance." | ( Gupta, N; Kalichman, MW; Mizisin, AP; Weinreb, RN; Yücel, YH; Zhang, Q, 2006) |
| "IOP elevation was treated with antiglaucoma medication in all but one eye (0." | ( Konstantopoulos, A; Luff, AJ; Newsom, RS; Williams, CP, 2007) |
| "Subject age, gender, diagnosis and treatment for glaucoma, use of systemic steroids, procedure performed and pre-operative and post-operative IOP in the primary position and in upgaze, were all evaluated." | ( Buil, JA; Crespí, J; Rodríguez, F, 2007) |
| "Present treatments for all glaucoma patients are inadequate and a goal to rectify this is to discover appropriate drugs or chemicals (neuroprotectants) that can be taken orally to slow down retinal ganglion cell death and have negligible side-effects." | ( Osborne, NN, 2009) |
| "To date, treatment of glaucoma has focused on lowering intraocular pressure (IOP) though there are other mechanisms that might damage the optic nerve, leading to characteristic visual field loss." | ( Good, TJ; Kahook, MY, 2010) |
| "Thus, treatment of glaucoma is focused on lowering of intraocular pressure and preventing the occurrence or progression of glaucomatous optic neuropathy." | ( Fromm, M; Rosenthal, R, 2011) |
| "Currently, the only treatment option of glaucoma is reduction of intraocular pressure." | ( Hakkola, J; Mäenpää, J; Pelkonen, O; Vapaatalo, H; Volotinen, M, 2011) |
| "To study compliance in the medical treatment of glaucoma, its possible association with other factors, and quality of life of patients with glaucoma." | ( Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011) |
| "Compliance is very important in the treatment of glaucoma, and our study provides objective data through the use of Travalert dosing aid with relative compliances of 70%." | ( Escalada, A; García Sánchez, J; García-Feijoó, J; Martínez-de-la-Casa, JM; Sáenz-Francés, F; Sánchez-Pulgarín, M, 2011) |
| "Without treatment, glaucoma can cause blindness within a few years; consequently glaucoma has to be diagnosed before long-term visual loss occurs." | ( Benitez-del-Castillo, JM; Colligris, B; Crooke, A; Escribano, J; García-Feijoo, J; Gasull, X; Herrero-Vanrell, R; Pintor, J, 2012) |
| "He was treated with antiglaucoma drugs and artificial tears as an outpatient." | ( Aksoy, A; Aslan, L; Aslankurt, M; Başkan, AM, 2013) |
| "An untreated glaucomatous group was used as control." | ( Bravo, R; Cardoso, VN; Castilho, RO; Cronemberger, S; Faraco, AA; Fernandes, SO; Ferreira, AJ; Foureaux, G; Franca, JR; Fuscaldi, LL; Ribeiro, TG; Rodrigues, LB; Yoshida, MI, 2014) |
| "for the treatment of glaucoma and ocular hypertension." | ( Garnock-Jones, KP, 2014) |
| "This is especially true for the treatment of glaucoma and the high risk factor often associated with this ocular disease, elevated intraocular pressure (IOP)." | ( Sharif, NA, 2015) |
| "Four eye drops to treat glaucoma--Xalatan (latanoprost 50 μg/mL; Pfizer), Monoprost (latanoprost 50 μg/mL; Théa Pharma), Taflotan Sine (tafluprost 15 μg/mL; Santen Pharmaceutical Co." | ( Dutescu, RM; Panfil, C; Pinheiro, R; Schrage, N, 2016) |
| "Therefore, cannabis treatment for glaucoma currently seems impractical and is not recommended by either the Israeli or the American glaucoma societies." | ( Geyer, O; Mathalone, N; Wolf, A, 2015) |
| "In cases where such treatment fails, glaucoma-filtering surgery is considered, most commonly trabeculectomy surgery with variations in technique, for example, the type of conjunctival flap (fornix- or limbal-based)." | ( Abdulaal, M; Al-Haddad, C; Al-Moujahed, A; Ervin, AM, 2015) |
| "Trabeculectomy is performed as a treatment for glaucoma to lower intraocular pressure (IOP)." | ( Cheng, JW; Cheng, SW; Lu, GC; Wei, RL, 2016) |
| "Current treatment of glaucoma relies on administration of daily drops or eye surgery." | ( Borrás, T; Buie, LK; Spiga, MG, 2016) |
| "Although challenges in medical treatment of glaucoma exist, particularly in patient adherence, medical therapy remains the first line treatment for almost all glaucoma patients." | ( Novack, GD; Robin, AL; Schehlein, EM, 2017) |
| "The therapeutic efficacies in treating glaucomatous damage are in response to in vivo pilocarpine release profiles modulated by the carbon number of thermo-responsive polymer segment-mediated carrier hydrophobicity and degradability." | ( Lai, JY; Luo, LJ, 2017) |
| "The primary treatment for glaucoma aims to lower intraocular pressure (IOP) with the use of topical medicines." | ( Wang, X; Wu, M; Xu, L, 2017) |
| "Beta-blocker is the first choice treatment for glaucoma in pregnancy but, when necessary, multidrug therapy should not to be excluded." | ( Caruso, A; Chiaradia, G; D'Oria, L; De Luca, C; De Santis, M; Licameli, A; Neri, C; Nucci, M; Pellegrino, M; Visconti, D, 2018) |
| "Long-term treatment of glaucoma, a major leading cause of blindness, is challenging due to poor patient compliance." | ( Asada, H; Aya-Shibuya, E; Bhisitkul, RB; Bloomer, MM; da Silva, NRK; Desai, TA; Kim, J; Kudisch, M; Mudumba, S, 2018) |
| "Morever, the treatment of glaucomatous rabbits with liposome formulations containing TQ in their preparation [Lip (TQ) and Lip (LAT + TQ)] greatly improved the ocular tissue-induced histopathological lesions." | ( El-Gohary, AA; Fahmy, HM; Gaber, MH; Mohamed, FF; Saad, EAES; Sabra, NM, 2018) |
| "Current ophthalmic drug delivery to treat glaucoma is mostly eyedrop, whose rapid elimination on corneal surface can lead to poor bioavailability." | ( Chen, J; Huang, J; Huang, Y; Huang, Z; Li, Y; Pan, X; Wu, C; Zeng, Y, 2018) |
| "Glaucomas treatment." | ( Bluwol, E, 2016) |
| "Ripasudil was safe and effective in the treatment of glaucoma and OH in Japanese patients, with a low incidence of ADRs or treatment discontinuation, and reduced IOP after 3 months of treatment." | ( Gunji, R; Imada, R; Kakuda, T; Kanno, T; Sano, T; Shingaki, W; Tanihara, H, 2019) |
| "The current clinical treatment for glaucoma involves controlling intraocular pressure with drugs or surgery; however, some patients still progressively lose their eyesight." | ( Chen, Q; He, Z; Li, Y; Xi, X; Zeng, Y; Zhao, J, 2019) |
| "Primary treatment for glaucoma relies on chronic instillation (daily) of intraocular pressure (IOP) lowering eye drops." | ( Guzman-Aranguez, A; Kaur, IP; Perez de Lara, MJ; Singh, J; Singh, M; Yadav, M, 2019) |
| "Initial treatment of glaucoma commonly involves using anti-glaucoma medications either as monotherapy or combination therapy." | ( Mehran, NA; Razeghinejad, R; Sinha, S, 2020) |
| "In a cohort of 3883 medically treated glaucoma patients, glaucoma suspect, or patients with ocular hypertension assembled in 2001-2004, 1639 were deceased." | ( Beckers, HJM; Berendschot, TTJM; Mokhles, P; Schouten, JSAG; van Gorcom, L; Webers, CAB, 2021) |
| "Of these, 42 patients with treated open-angle glaucoma and moderate visual field loss in at least 1 eye were selected for inclusion and randomized." | ( Blumberg, DM; Cioffi, GA; De Moraes, CG; John, SWM; Liebmann, JM; Williams, PA, 2022) |
| "STATEMENT OF SIGNIFICANCE: To treat glaucoma, conventional eye drops are often prescribed; however, they often require multiple daily administrations due to rapid preocular clearance." | ( Choy, YB; Ha, A; Kim, SN; Kim, YK; Lee, SH; Min, CH; Park, CG; Park, KH, 2022) |
| "Timolol maleate is used for the treatment of glaucoma and metabolized by cytochrome CYP2D6 in the liver." | ( Akmalova, KA; Fisenko, VP; Grishina, EA; Ivashchenko, DV; Kachanova, AA; Moshetova, LK; Soshina, MM; Sozaeva, ZA; Sychev, DA; Turkina, KI; Zastrozhin, MS, 2023) |
| "Current treatments for glaucoma only slow or partially prevent the disease progression, failing to prevent RGCs death and visual field defects completely." | ( Ji, D; Li, H; Liu, M; Xia, X; Yang, R, 2022) |
| "The main goal of treatment for any glaucoma patient is to reduce the intraocular pressure." | ( Aberkane, D; Acheli, A; Boudedja, H; Boulanab, F; Derdour, A; Djabour, M; Garout, R; Ghemri, N; Lazreg, S; Zine El Abidine, N, 2023) |
| "The use of marijuana for the treatment of glaucoma has been widely debated amongst ophthalmologists and glaucoma specialists." | ( Khouri, AS; Oydanich, M; Shah, R; Yakobashvili, D, 2023) |
| "Brimonidine is used to treat glaucoma and other eye conditions." | ( Alkahtani, HM; Alomar, AM; Bakheit, AH; Darwish, H, 2023) |
| "Pharmacotherapy is the mainstay of treatment for glaucoma patients." | ( Kavitha, S; Subbulakshmi, S; Venkatesh, R, 2023) |
| "A major challenge in the topical treatment of glaucoma patients is the many side effects and the resulting reduced adherence." | ( Hedengran, A; Kolko, M, 2023) |
| "First-line treatment for glaucoma relies on the administration of prostaglandin analogs, with latanoprost being the most widely used." | ( Cwiklik, L; Daull, P; Garrigue, JS; Olżyńska, A; Riedlová, K; Saija, MC; Vazdar, K, 2023) |